Use of Azoles for Systemic Antifungal Therapy

Advances in Pharmacology

Volumn 39, Issue C, 1997, Pages 143-189

  Kauffman, Carol A ^a   Carver, Peggy L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TRIAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; DRUG INTERACTION; HUMAN; MYCOSIS; REVIEW;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; IMIDAZOLES; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MYCOSES; TRIAZOLES;

EID: 0030633665     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60071-X     Document Type: Article

References (314)

1. Adam R.D., Paquin M.L., Petersen E.A., Saubolle M.A., Rinaldi M.G., Corcoran J.G., Galgiani J.N., and Sobonya R.E. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature. Medicine (Baltimore) 65 (1986) 203-217
2. S. Akkerman V. Lampasona S. Dix H. Zhang J. Wingard R. Saral (1993). Pharmaco-kinetics of fluconazole in autologous bone marrow transplant patients prior to and after the development of chemotherapy-induced mucositis. Intersci. Conf. Antimicrob. Agents Chemother., 33rd, New Orleans, Abstr. No.1434
3. Akler M.E., Vellend H., McNeely D.M., Walmsley S.L., and Gold W.L. Use of fluconazole in the treatment of candidal endophthalmitis. Clin. Infect. Dis. 20 (1995) 657-664
4. Alderman C.P., and Jersmann H.P. Digoxin-itraconazole interaction (letter). Med. J. Aust. 159 (1993) 838-839
5. Anaissie E., Bodey G.P., Kantarjian H., David C., Barnett K., Bow E., de Felice R., Downs N., File T., Karam G., Potts D., Shelton M., and Sugar A. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91 (1991) 142-150
6. Anaissie E.J., Vartivarian S.E., Abi-said D., Uzun O., Pinczowski H., Kontoyiannis D.P., Khoury P., Papadakis K., Gardner A., Raad I.I., Gilbreath J., and Bodey G.P. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. 101 (1996) 170-176
7. Apseloff G., Hilligoss D.M., Gardner M.J., Henry E.B., Inskeep P.B., Gerber N., and Lazar J.D. Induction of fluconazole metabolism by rifampin: In vivo study in humans. J. Clin. Pharmacol. 31 (1991) 358-361
8. Arndt C.A., Walsh T.J., McCulley C.L., Balis F.M., Pizzo P.A., and Poplack D.G. Fluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system. J. Infect. Dis. 157 (1988) 178-180
9. Assan R., Fredj G., Larger E., Feutren G., and Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab. 20 (1994) 49-52
10. Baciewicz A.M., and Baciewicz Jr. F.A. Ketoconazole and fluconazole drug interactions. Arch. Intern. Med. 153 (1993) 1970-1976
11. Baciewicz A.M., Menke J.J., Bokar J.A., and Baud E.B. Fluconazole-warfarin interaction (letter). Ann. Pharmacother. 28 (1994) 1111
12. Back D.J., and Tjia J.F. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br. J. Clin. Pharmacol. 32 (1991) 624-626
13. Back D.J., Stevenson P., and Tjia J.F. Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br. J. Clin. Pharmacol. 28 (1989) 166-170
14. Bagnarello A.G., Lewis L.A., McHenry M.C., Weinstein A.J., Naito H.K., McCullough A.J., Lederman R.J., and Gavan T.L. Unusual serum lipoprotein abnormality induced by the vehicle of miconazole. N. Engl. J. Med. 296 (1977) 497-499
15. Barbara G., Barbarini G., and di Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: A double-blind, randomized, controlled clinical study. Scand. J. Infect. Dis. 27 (1995) 613-617
16. Barone J.A., Koh J.G., Bierman R.H., Colaizzi J.L., Swanson K.A., Gaffar M.C., Moskovitz B.L., Mechlinski W., and van de Velde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob. Agents Chemother. 37 (1993) 778-784
17. Bart-Delabesse E., Boiron P., Carlotti A., and Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J. Clin. Microbiol. 31 (1993) 2933-2937
18. Bennett J.E., and Remington J.S. Miconazole in cryptococcosis and systemic candidiasis: A word of caution. Ann. Intern. Med. 94 (1981) 708-709
19. Beyer G.P.J., and Voorhoeve-den Hartog H.J. Day-to-day follow-up after a short oral treatment of acute vaginal candidosis with itraconazole. Mycoses 35 (1992) 99-101
20. Binder R.E., Faling J., Pugatch R.D., Mahasaen C., and Snider G.L. Chronic necrotizing pulmonary aspergillosis: A discrete clinical entity. Medicine (Baltimore) 61 (1982) 109-124
21. Blatchford N.R. Treatment of oral candidosis with itraconazole: A review. J. Am. Acad. Dermatol. 23 (1990) 565-567
22. Blum R.A., D'Andrea D.T., Florentino B.M., Wilton J.H., Hilligoss D.M., Gardner M.J., Henry E.B., Goldstein H., and Schentag J.J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann. Intern. Med. 114 (1991) 755-757
23. Blum R.A., Wilton J.H., Hilligoss D.M., Gardner M.J., Henry E.B., Harrison N.J., and Schentag J.J. Effect of fluconazole on the disposition of phenytoin. Clin. Pharmacol. Ther. 49 (1991) 420-425
24. Bodey G.P. Azole antifungal agents. Clin. Infect. Dis. 14 Suppl. 1 (1992) S161-S169
25. Boelaert J., Schurgers M., Matthys E., Daneels R., Van Peer A., De Beule K., Woestenborghs R., and Heykants J. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob. Agents Chemother. 32 (1988) 1595-1597
26. Bozzette S.A., Gordon R.L., Yen A., Rinaldi M., Ito M.K., and Fierer J. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: Case report. Clin. Infect. Dis. 15 (1992) 701-703
27. Bradsher R.W., Rice D.C., and Abernathy R.S. Ketoconazole therapy for endemic blastomycosis. Ann. Intern. Med. 103 (1985) 872-879
28. Brammer K.W., Farrow P.R., and Faulkner J.W. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12 Suppl. 3 (1990) S318-S326
29. Brass C., Galgiani J.N., Blaschke T.F., de Felice R., O'Reilly R.A., and Stevens D.A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chemother. 21 (1982) 151-158
30. Brooks B.J., Williams W.L., Sanders C.V., and Marier R.L. Apparent ketoconazole failure in candidal cholecystitis. Arch. Intern. Med. 142 (1982) 1934-1935
31. Brugmans J., Van Cutsem J., Heykants J., Schuermans V., and Thienpont D. Systemic antifungal potential, safety, biotransport and transformation of miconazole nitrate. Eur. J. Clin. Pharmacol. 5 (1972) 93-99
32. Bruzzese V.L., Gillum J.G., Israel D.S., Johnson G.L., Kaplowitz L.G., and Polk R.E. Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 39 (1995) 1050-1053
33. Budtz-Jorgensen E., Holmstrup P., and Krogh P. Fluconazole in the treatment of Candida-associated denture stomatitis. Antimicrob. Agents Chemother. 32 (1988) 1859-1863
34. Cadle R.M., Zenon G.J., Rodriguez-Barradas M.C., and Hamill R.J. Fluconazole-induced symptomatic phenytoin toxicity. Ann. Pharmacother. 28 (1994) 191-195
35. Calhoun D.L., Waskin H., White M.P., Bonner J.R., Mulholland J.H., Rumans L.W., Stevens D.A., and Galgiani J.N. Treatment of systemic sporotrichosis with ketoconazole. Rev. Infect. Dis. 13 (1991) 47-51
36. Canafax D.M., Graves N.M., Hilligoss D.M., Carleton B.C., Gardner M.J., and Matas A.J. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 51 (1991) 1014-1018
37. Carlson J.A., Mann H.J., and Canafax D.M. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am. J. Hasp. Pharm. 40 (1983) 1334-1336
38. Cartledge J., Midgley J., Youle M., and Gazzard B. Itraconazole cyclodextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy. J. Antimicrob. Chemother. 33 (1994) 1071-1073
39. Carver P.L., Berardi R.R., Knapp M.J., Rider J.M., Kauffman C.A., Bradley S.F., and Atassi M. In vivo interaction of ketoconazole and sucralfate in healthy volunteers. Antimicrob. Agents Chemother. 38 (1994) 326-329
40. Castiglia M., Smego R.A., and Sames E.L. Candida endocarditis and amphotericin B intolerance: Potential role for fluconazole. Infect. Dis. Clin. Pract. 3 (1994) 248-253
41. Catanzaro A., Einstein H., Levine B., Ross J.B., Schillaci R., Fierer J., and Friedman P.J. Ketoconazole for treatment of disseminated coccidioidomycosis. Ann. Intern. Med. 96 (1982) 436-440
42. Catanzaro A., Galgiani J.N., Levine B.E., Sharkey-Mathis P.K., Fierer J., Stevens D.A., Chapman S.W., and Cloud G. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am. J. Med. 98 (1995) 249-256
43. Cauwenbergh G. Cryptococcal meningitis: The place of itraconazole. Mycoses 36 (1993) 221-228
44. Cheng I.K.P., Fang G.-X., Chan T.-M., Chan P.C.K., and Chan M.-K. Fungal peritonitis complicating peritoneal dialysis: Report of 27 cases and review of treatment. Q.J. Med. 71 (1989) 407-416
45. Chin T.W., Loeb M., and Fong I.W. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob. Agents Chemother. 39 (1995) 1671-1675
46. Classen D.C., Burke J.P., and Smith C.B. Treatment of coccidioidal meningitis with fluconazole. J. Infect. Dis. 158 (1988) 903-904
47. Cleary J.D., Taylor J.W., and Chapman S.W. Itraconazole in antifungal therapy. Ann. Pharmacother. 26 (1992) 502-509
48. Coker R.J., Tomlinson D.R., Parkin J., Harris J.R., and Pinching A.J. Interaction between fluconazole and rifampicin. Br. Med. J. 301 (1990) 818
49. Como J.A., and Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330 (1994) 263-272
50. Conti Diaz I.A., Civila E., Gezuele E., Lowinger M., Calegari L., Sanabria D., Fuentes L., de Rosa D., and Alzueta G. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 35 (1992) 153-156
51. Crane J.K., and Shih H.T. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am. J. Med. 95 (1993) 445-446
52. Craven P.C., Graybill J.R., Jorgensen J.H., Dismukes W.E., and Levine B.E. High-dose ketoconazole for treatment of fungal infections of the central nervous system. Ann. Intern. Med. 98 (1983) 160-167
53. Crussell-Porter L.L., Rindone J.P., Ford M.A., and Jaskar D.W. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch. Intern. Med. 153 (1993) 102-104
54. Czwerwie C.F.S., Bilsker M.S., Kamerman M.L., and Bisno A.L. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am. J. Med. 94 (1993) 545-546
55. Dall I., and Salzman G. Treatment of pulmonary sporotrichosis with ketoconzole. Rev. Infect. Dis. 9 (1987) 795-798
56. Dan Priel I. Failure of fluconazole therapy for sternal osteomyelitis due to Candida albicans. Clin. Infect. Dis. 18 (1994) 126-127
57. Daneshmend T.K., and Warnock D.W. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. 14 (1988) 13-34
58. Daneshmend T.K., Warnock D.W., Ene M.D., Johnson E.M., Parker G., Richardson M.D., and Roberts C.J. Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J. Antimicrob. Chemother. 12 (1983) 185-188
59. Daneshmend T.K., Warnock D.W., Ene M.D., Johnson E.M., Potten M.R., Richardson M.D., and Williamson P.J. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob. Agents Chemother. 25 (1984) 1-3
60. De Beule K., De Doncker P., Cauwenbergh G., Koster M., Legendre R., Blatchford N., Daunas J., and Chwetzoff E. The treatment of aspergillosis and aspergilloma with itraconazole, clinical results of an open international study (1982-1987). Mycoses 31 (1988) 476-485
61. De K. Beule P.H. Jacqmin, Van A. Peer P. Stoffels J. Heykants (1995). The pharmacokinetic rationale behind intravenous itraconazole. Intersci. Conf. Antimicrob. Agents Chemother. 35th, San Francisco, Abstr. No. A75
62. Debruyne D., Ryckelynck J.-P., Moulin M., Hurault de Ligny B.H., Levaltier B., and Bigot M.C. Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin. Pharmacokinet. 18 (1990) 491-498
63. de Felice R., Galgiani J.N., Campbell S.C., Palpant S.D., Friedman B.A., Dodge R.R., Weinberg M.G., Lincoln L.J., Tennican P.C., and Barbee R.A. Ketoconazole treatment of nonprimary coccidioidomycosis. Evaluation of 60 patients during three years of study. Am. J. Med. 72 (1982) 681-687
64. de Gans J., Portegies P., Tiessens G., Eeftinck Schattenkerk J.K., van Boxtel C.J., van Ketel R.J., and Stam J. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 6 (1992) 185-190
65. del Palacio A., Cuetara M.S., Ferro M., Perez-Blazquez E., Lopez-Sana J.A., Roiz M.P., Carnevali D., and Noriega A.R. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 36 (1993) 193-199
66. Denning D.W., and Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: Review of 2121 published cases. Rev. Infect. Dis. 12 (1990) 1147-1201
67. Denning D.W., Tucker R.M., Hanson L.H., Hamilton J.R., and Stevens D.A. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch. Intern. Med. 149 (1989) 2301-2308
68. Denning D.W., Tucker R.M., Hanson L.H., and Stevens D.A. Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86 (1989) 791-800
69. Denning D.W., Lee J.Y., Hostetler J.S., Pappas P., Kauffman C.A., Dewsnup D.H., Galgiani J.N., Graybill J.R., Sugar A.M., Catanzaro A., Gallis H., Perfect J.R., Dockery B., Dismukes W.E., and Stevens D.A. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. Am. J. Med. 97 (1994) 135-144
70. de Pauw B.E., Raemaekers J.M.M., Donnelly J.P., Kullberg B.J., and Meis J.F.G.M. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann. Hematol. 70 (1995) 83-87
71. Deresinski S.C., Lilly R.B., Levine H.B., Galgiani J.N., and Stevens D.A. Treatment of fungal meningitis with miconazole. Arch. Intern. Med. 137 (1977) 1180-1185
72. de Wit S.D., Weerts D., Goossens H., and Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1 (1989) 746-748
73. Dewsnup D.H., Galgiani J.N., Graybill J.R., Diaz M., Rendon A., Cloud G.A., and Stevens D.A. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis. Ann. Intern. Med. 124 (1996) 305-310
74. Diaz M., Puente R., de Hoyos L.A., and Cruz S. Itraconazole in the treatment of coccidioidomycosis. Chest 100 (1991) 682-684
75. Diaz M., Negroni R., Montero-Gei F., Castro L.G.M., Sampaio S.A.P., Borelli D., Restrepo A., Franco L., Bran J.L., Arathoon E.G., and Stevens D.A. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin. Infect. Dis. 14 Suppl. 1 (1992) S68-S76
76. Dismukes W.E., Stamm A.M., Graybill J.R., Craven P.C., Stevens D.A., Stiller R.L., Sarosi G.A., Medoff G., Gregg C.R., Gallis H.A., Fields B.T., Marier R.L., Kerkering T.A., Kaplowitz L.G., Cloud G., Bowles C., and Shadomy S. Treatment of systemic mycoses with ketoconazole: Emphasis on toxicity and clinical response in 52 patients. Ann. Intern. Med. 98 (1983) 13-20
77. Dismukes W.E. Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial. Ann. Intern. Med. 103 (1985) 861-872
78. Dismukes W.E., Bradsher R.W., Cloud G.C., Kauffman C.A., Chapman S.W., George R.B., Stevens D.A., Girard W.M., Saag M.S., and Bowles-Patton C. Itraconazole therapy for blastomycosis and histoplasmosis. Am. J. Med. 93 (1992) 489-497
79. Dixon D.M., Shadomy H.J., Espinel-Ingroff A., and Kerkering T.M. Comparison of the in vitro antifungal activities of miconazole and a new imidazole, R41,400. J. Infect. Dts. 138 (1978) 245-248
80. Doble N., Shaw R., Rowland-Hill C., Lusk M., Warnock D.W., and Keal E.E. Pharmacokinetic study of the interaction between rifampin and ketoconazole. J. Antimi-crob. Chemother. 21 (1988) 633-635
81. Drayton J., Dickinson G., and Rinaldi M.G. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole (letter). Clin. Infect. Dis. 18 (1994) 266
82. Drouhet E., and Dupont B. Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am. J. Med. 74, Suppl. IB (1983) 30-47
83. Ducharme M.P., Slaughter R.L., Warbasse L.H., Chandrasekar P.H., van de Velde V., Mannens G., and Edwards D.J. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin. Pharmacol. Ther. 58 (1995) 617-624
84. Duggan J.M., Wolf M.D., and Kauffman C.A. Phialophora verrucosa infection in an AIDS patient. Mycoses 38 (1995) 215-218
85. Dupont B. Itraconazole therapy in aspergillosis: Study in 49 patients. J. Am. Acad. Dermatol. 23 (1990) 607-614
86. Dupont B., and Drouhet E. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J. Med. Vet. Mycol. 26 (1988) 67-71
87. Dworzack D.L., Clark R.B., Borkowski W.J., Smith D.L., Dykstra M., Pugsley M.P., Horowitz E.A., Connolly T.L., McKinney D.L., Hostetler M.K., Fitzgibbons J.F., and Galant M. Pseudalleschena boydii brain abscess: Association with near-drowning and efficacy of high-dose prolonged miconazole therapy in patients with multiple abscesses. Medicine (Baltimore) 68 (1989) 218-224
88. Eng R.H.K., Person A., Mangura C., Chmel H., and Corrado M. Susceptibility of zygomycetes to amphotericin B, miconazole and ketoconazole. Antimicrob. Agents Chemother. 20 (1981) 688-690
89. Espinel-Ingroff A., Shadomy S., and Gebhart R.J. In vitro studies with R51,211 (Itraconazole). Antimicrob. Agents Chemother. 26 (1984) 5-9
90. Evans T.G., Mayer J., Cohen S., Classen D., and Carroll K. Fluconazole failure in the treatment of invasive mycoses. J. Infect. Dis. 164 (1991) 1232-1235
91. Fan-Havard P., O'Donovan C., Smith S.M., Oh J., Bamberger M., and Eng R.H.K. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin. Infect, Dis. 21 (1995) 960-965
92. First M.R., Schroeder T.J., Weiskittel P., Myre S.A., Alexander J.W., and Pesce A.J. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 2 (1989) 1198-1201
93. First M.R., Schroeder T.J., Alexander J.W., Stephens G.W., Weiskittel P., Myre S.A., and Pesce A.J. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 51 (1991) 365-370
94. First M.R., Schroeder T.J., Michael Hariharan A.S., Weiskittel P., and Alexander J.W. Cyclosporine-ketoconazole interaction. Long-term follow-up and preliminary results of a randomized trial. Transplantation 55 (1993) 1000-1004
95. Fisher J.F., Newman C.L., and Sobel J.D. Yeast in the urine: Solution for a budding problem. Clin. Infect. Dis. 20 (1995) 183-189
96. Foulds G., Brennan D.R., Wajszczuk C., Cantanzaro A., Garg D.C., Knopf W., Rinaldi M., and Weidler D.J. Fluconazole penetration into cerebrospinal fluid in humans. J. Clin. Pharmacol. 28 (1988) 363-366
97. Franklin I.M., Elias E., and Hirsch C. Fluconazole-induced jaundice (letter). Lancet 336 (1990) 565
98. Fromtling R.A. Overview of medically important antifungal azole derivatives. Clin. Microbiol. Rev. 1 (1988) 187-217
99. Galgiani J.N. Coccidioidomycosis. West. J. Med. 159 (1993) 153-171
100. Galgiani J.N., Stevens D.A., Graybill J.R., Dismukes W.E., and Cloud G.A. Ketoconazole therapy of progressive coccidioidomycosis: Comparison of 400 and 800 mg doses and observations at higher doses. Am. J. Med. 84 (1988) 603-610 the NIAID Mycoses Study Group
101. Galgiani J.N., Catanzaro A., Cloud G.A., Higgs J., Friedman B.A., Larsen R.A., and Graybill J.R. Fluconazole therapy for coccidiodal meningitis. Ann. Intern. Med. 119 (1993) 28-35 the NIAID Mycoses Study Group
102. Gearhart M.O. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann. Pharmacother. 28 (1994) 1177-1181
103. Gericke K.R. Possible interaction between warfarin and fluconazole. Pharmacotberapy 13 (1993) 508-509
104. Gillum J.G., Israel D.S., and Polk R.E. Pharmacokinetic drug interactions with antimicrobial agents. Clin. Pharmacokinet. 25 (1993) 450-482
105. Goldberg S.L., Geha D.J., Marshall W.F., Inwards D.J., and Hoagland H.C. Successful treatment of simultaneous pulmonary Pseudallescberia boydii and Aspergillus terreus infection with oral itraconazole. Clin. Infect. Dis. 16 (1993) 803-805
106. Goldway M., Teff D., Schmidt R., Oppenheim A.B., and Koltin Y. Multidrug resistance in Candida albicans: Disruption of the BEN R gene. Antimicrob. Agents Chemother. 39 (1995) 422-426
107. Gomez D.Y., Wacher V.J., Tomlanovich S.J., Hebert M.F., and Benet L.Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58 (1995) 15-19
108. Goodman J.L., Winston D.J., Greenfield R.A., Chandrasekar P.H., Fox B., Kaizer H., Shadduck R.K., Shea T.C., Stiff P., Friedman D.J., Powderly W.G., Silber J.L., Horowitz H., Lichtin A., Wolff S.N., Mangan K.F., Silver S.M., Weisdorf D., Ho W.G., Gilbert G., and Buell D. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326 (1992) 845-851
109. Gradon J.D., and Sepkowitz D.V. Massive hepatic enlargement with fatty change associated with ketoconazole. DICP 24 (1990) 1175-1176
110. Graninger W., Presteril E., Schneeweiss B., Teleky B., and Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J. Infect. 26 (1993) 133-146
111. Graybill J.R., and Levine H.B. Successful treatment of cryptococcal meningitis with intraventricular miconazole. Arch. Intern. Med. 138 (1978) 814-816
112. Graybill J.R., Galgiani J.N., Jorgensen J.H., and Strandberg D.A. Ketoconazole therapy for fungal urinary tract infections. J. Urol. 129 (1983) 68-70
113. Graybill J.R., Stevens D.A., Galgiani J.N., Dismukes W.E., and Cloud G.A. Itraconazole treatment of coccidioidomycosis. Am. J. Med. 89 (1990) 282-290 the MAID Mycoses Study Group
114. J.R. Graybill J. Vazquez R.O. Darouiche R. Morhart B.L. Moskovitz I. Mallegol (1995). Itraconazole oral solution versus fluconazole treatment of oropharyngeal candidiasis. Intersci. Conf. Antimicrob. Agents Chemother., 35th, San Francisco, Abstr. No. 1220
115. Groves J.T., and Gross Z. On the mechanism of epoxidation and hydroxylation catalyzed by iron porphyrins. Evidence for non-intersecting reaction pathways. In: Kessissoglou D.P. (Ed). "Bioin-organic Chemistry: An Inorganic Perspective of Life" (1995), Kluwer Academic Publishers, Dordrecht, The Netherlands 39-47 NATO ASI Sen
116. Gussenhoven M.J.E., Haak A., Peereboom-Wynia J.D.R., and Van't Wout J.W. Stevens-Johnson syndrome after fluconazole. Lancet 338 (1991) 120
117. Hanger D.P., Jevons S., and Shaw J.T. Fluconazole and testosterone: In vivo and in vitro studies. Antimicrob. Agents Chemother. 32 (1988) 646-648
118. J. Hardin D. Lange J. Heykants C. Ding, Van De V. Velde C. Slusser M. Klausner (1995a). The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients. Intersci. Conf. Antimicrob. Agents Chemother., 35th, San Francisco, Abstr. No. A21
119. Hardin T.C., Graybill J.R., Fetchick R., Woestenborghs R., Rinaldi M.G., and Kuhn J.G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob. Agents Chemother. 32 (1988) 1310-1313
120. T.C. Hardin P.K. Sharkey-Mathis M.G. Rinaldi J.R. Graybill (1995b). Evaluation of the pharmacokinetic interaction between itraconazole and didanosine in HIV-infected subjects. Intersci. Conf. Antimicrob. Agents Chemother., 35th, San Francisco, Abstr. No. A29
121. Hay R.J., Clayton Y.M., Moore M.K., and Midgley G. An evaluation of itraconazole in the management of onychomycosis. Br. J. Dermatol. 119 (1988) 359-366
122. He X., Tiballi R.N., Zarins L.T., Bradley S.F., Sangeorzan J.A., and Kauffman C.A. Azole resistance in oropharyngeal Candida albicans strains isolated from patients with HIV infection. Antimicrob. Agents Chemother. 38 (1994) 2495-2497
123. Heel R.C., Brogden R.N., Pakes G.E., Speight T.M., and Avery G.S. Miconazole: A preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs 19 (1980) 7-30
124. Heel R.C., Brogden R.N., Carmine A., Morley P.A., Speight T.M., and Avery G.S. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 38 (1982) 1-36
125. Heykants J., Van Peer A., Van de Velde V., Van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., Van Cutsem J., and Cauwenbergh G. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 32 Suppl. 1 (1989) 67-87
126. Hitchcock C.A. Resistance of Candida albicans to azole antifungal agents. Biochem. Soc. Trans. 21 (1993) 1039-1047
127. Hitchcock C.A., Pye G.W., Troke P.F., Johnson E.M., and Warnock D.W. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37 (1993) 1962-1965
128. Hoeprich P., and Goldstein E. Miconazole therapy for coccidioidomycosis. J. Am. Med. Assoc. 230 (1974) 1153-1157
129. Hoeschele J.D., Roy A.K., Pecoraro V.L., and Carver P.L. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob. Agents Chemother. 38 (1994) 319-325
130. Holt R.J., and Azmi A. Miconazole-resistant Candida. Lancet 1 (1978) 50-51
131. Honig P.K., Wortham D.C., Zamani K., Conner D.P., Mullin J.C., and Cantilena L.R. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardio-graphic consequences. J. Am. Med. Assoc. 269 (1993) 1513-1518
132. Honig P.K., Wortham D.C., Zamani K., Mullin J.C., Conner D.P., and Cantilena L.R. The effect of fluconazole on the steady-state pharmacokinetics and electro-cardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther. 53 (1993) 630-636
133. Honig P.K., Wortham D.C., Hull R., Zamani K., Smith J.E., and Cantilena L.R. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33 (1993) 1201-1206
134. Horsburgh C.R., and Kirkpatrick C.H. Long-term therapy of chronic mucocutaneous candidiasis and ketoconazole: experience with twenty-one patients. Am. J. Med. 74 Suppl. 1B (1983) 23-29
135. Horsburgh Jr. C.R., Cannady Jr. P.B., and Kirkpatrick C.H. Treatment of fungal infections in the bones and joints with ketoconazole. J. Infect. Dis. 147 (1983) 1064-1069
136. Horton C.M., Freeman C.D., Nolan Jr. P.E., and Copeland J.G. Cyclosporine interactions with miconazole and other azole-antimycotics: A case report and review of the literature. J. Heart Lung Transplant. 11 (1992) 1127-1132
137. Houang E.T., Chappatte O., Byrne D., Macrae P.V., and Thorpe J.E. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob. Agents. Chemother. 34 (1990) 909-910
138. Humphrey M.J., Jevons S., and Tarbit M.H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28 (1985) 648-653
139. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn. Microbiol. Infect. Dis. 12 (1989) 239S-247S
140. Jacobs L.G., Skidmore E.A., Freeman K., Lipshultz D., and Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin. Infect. Dis. 22 (1996) 30-35
141. Jacobson M.A., Hanks D.K., and Ferrell L.D. Fatal hepatic necrosis due to fluconazole. Am. J. Med. 96 (1994) 188-190
142. Janssen P.A.J., and Symoens J.E. Hepatic reactions during ketoconasole treatment. Am. J. Med. 74 Suppl. IB (1983) 80-85
143. Johnson P.C., Khardori N., Najjar A.F., Butt F., Mansell P.W.A., and Sarosi G.A. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am. J. Med. 85 (1988) 152-158
144. Jordan W.M., Bodey G.P., Rodriguez J., Ketchel S.J., and Henney J. Miconazole therapy for treatment of fungal infections in cancer patients. Antimicrob. Agents Chemother. 16 (1979) 792-797
145. Karlix J.L., Cheng M.A., Brunson M.E., Ramos E.L., Howard R.J., Peterson J.C., Patton P.R., and Pfaff W.W. Decreased cyclosporine concentrations with the addition of an H2-receptor antagonist in a patient on ketoconazole. Transplantation 56 (1993) 1554-1555
146. Kauffman C.A. Newer developments in therapy for endemic mycoses. Clin. Infect. Dis. 19 Suppl. 1 (1994) S28-S32
147. Kauffman C.A. Old and new therapies for sporotrichosis. Clin. Infect. Dis. 21 (1995) 981-985
148. Kauffman C.A., and Bagnasco F.A. Digoxin toxicity associated with itraconazole therapy. Clin. Infect. Dis. 15 (1992) 886
149. Kauffman C.A., Bradley S.F., Ross S.C., and Weber D.R. Hepatospleniccandidasis: Successful treatment with fluconazole. Am. J. Med. 91 (1991) 137-141
150. Kauffman C.A., Bradley S.F., and Vine A.K. Candida endophthalmitis associated with intraocular lens implantation. Efficacy of fluconazole therapy. Mycoses 36 (1993) 13-17
151. Kauffman C.A. Role of Azoles in antifungal therapy. Clin. Infect. Dis. 22 Suppl. 2 (1996) S148-S153
152. Kauffman C.A., Pappas P.G., McKinsey D.S., Greenfield R.A., Perfect J.R., Cloud G.A., Thomas C.J., and Dismukes W.E. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. 22 (1996) 46-50 the NIAID Mycoses Study Group
153. Keogh A., Spratt P., McCosker C., Macdonald P., Mundy J., and Kann A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N. Engl. J. Med. 333 (1995) 628-633
154. Kintzel P.E., Rollins C.J., Yee W.J., and List A.F. Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill alloge-neic bone marrow transplant recipients. Ann. Pharmacother. 29 (1995) 140-143
155. Knapp M.J., Berardi R.R., Dressman J.B., Rider J.M., and Carver P.L. Modification of gastric pH with oral glutamic acid hydrochloride. Clin. Pharm. 10 (1991) 866-869
156. Knupp C.A., Brater D.C., Relue J., and Barbhaiya R.H. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J. Clin. Pharmacol. 33 (1993) 912-917
157. Koletar S.L., Russell J.A., Fass R.J., and Plouffe J.F. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 34 (1990) 2267-2268
158. Kramer M.R., Marshall S.E., Denning D.W., Keogh A.M., Tucker R.M., Galgiani J.N., Lewiston N.J., Stevens D.A., and Theodore J. Cyclosporine and itraconazole interactions in heart and lung transplant recipients. Ann. Intern. Med. 113 (1990) 327-329
159. Krishnaiah Y.S., Satyanarayana S., and Visweswaram D. Interaction between tolbuta-mide and ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 37 (1994) 205-207
160. Kujath P., and Lerch K. Secondary mycosis in surgery: Treatment with fluconazole. Infection 17 (1989) 111-117
161. Laine L., Dretler R.H., Conteas C., Tuazon C., Koster F.M., Sattler F., Squires K., and Islam M.Z. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann. Intern. Med. 117 (1992) 655-660
162. Lake-Bakaar G., Tom W., Lake-Bakaar D., Gupta N., Beidas S., Elsakr M., and Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 109 (1988) 471-473
163. Larsen R.A., Leal M.A.E., and Chan L.S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: A randomized trial. Ann. Intern. Med. 113 (1990) 183-187
164. Larsen R.A., Bozzette S.A., Jones B.E., Haghighat D., Leal M.A., Forthal D., Bauer M., Tilles J.G., McCutchan J.A., and Leedom J.M. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 19 (1994) 741-745
165. Lavrijsen A.P.M., Balmus K.J., Nugteren-Huying W.M., Roldaan A.C., Van't Wout J.W., and Strieker B.H.C. Hepatic injury associated with itraconazole. Lancet 340 (1992) 251-252
166. Lebech P.E. Treatment of vaginal candidiasis with a single dose of fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 364-367 the Multicenter Study Group
167. Lee B.E., Feinberg M., Abraham J.J., and Murthy A.R.K. Congenital malformation in an infant born to a woman treated with fluconazole. Pediatr. Infect. Dis. J. 11 (1992) 1062-1064
168. Lees R.S., and Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole (letter). N. Engl. J. Med. 333 (1995) 664-665
169. Lelawongs P., Barone J.A., Colaizzi J.L., Hsuan A.T., Mechlinski W., Legendre R., and Guarnieri J. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin. Pharm. 7 (1988) 228-235
170. Leu H.-S., and Huang C.-T. Clearance of funguria with short-course antifungal regimens: A prospective randomized, controlled study. Clin. Infect. Dis. 20 (1995) 1152-1157
171. Lewis J.H., Zimmerman H.J., Benson G.D., and Ishak K.G. Hepatic injury associated with ketoconazole therapy. Gastroenterology 86 (1984) 503-513
172. Lim S.G., Sawyeer A.M., Hudson M., Sercombe J., and Pounder R.E. Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. 3 (1993) 317-321
173. Lopes J.O., Alves S.H., Benevenga J.P., Salla A., Khmohan C., and Silva C.B. Subcutaneous pseudallescheriasis in a renal transplant recipient. Mycopathologia 125 (1994) 153-156
174. Lopez-Gil J.A. Fluconazole-cyclosporine interaction: a dose-dependent effect. Ann. Pharmacother. 27 (1993) 427-430
175. Lortholary O., Meyohas M.-C., Dupont B., Cadranel J., Salmon-Ceron D., Peyramond D., and Simonin D. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: Report of 33 cases. Am. J. Med. 95 (1993) 177-187
176. Maksymiuk A.W., Levine H.B., and Bodey G.P. Pharmacokinetics of ketoconazole in patients with neoplastic diseases. Antimicrob. Agents Cbemotber. 22 (1982) 43-46
177. Mannisto P.T., Mantyla R., Nykanen S., Lamminsivu U., and Ottoila P. Impairing effect of food on ketoconazole absorption. Antimicrob. Agents Cbemotber. 21 (1982) 730-733
178. May D.B., Drew R.H., Yedinak K.C., and Bartlett J.A. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmaco-therapy 14 (1994) 509-513
179. McClean K.L., and Sheehan G.J. Interaction between itraconazole and digoxin (letter). Clin. Infect. Dis. 18 (1994) 259-260
180. Mcllroy M.A. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis. J. Infect. Dis. 163 (1991) 420-421
181. McKinsey D.S., Gupta M.R., Driks M.R., Smith D.L., and O'Connor M. Histoplasmosis in patients with AIDS: Efficacy of maintenance amphotericin B therapy. Am. J. Med. 92 (1992) 225-227
182. McKinsey D.S., Kauffman C.A., Pappas P.G., Cloud G.A., Girard W.M., Sharkey P.K., Hamill R.J., Thomas C.J., and Dismukes W.E. Fluconazole therapy for histoplasmosis. Clin. Infect. Dis. 23 (1996) 996-1001 the NIAID Mycoses Study Group
183. McNulty R.M., Lazor J.A., and Sketch M. Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy. Clin. Pharm. 8 (1989) 222-225
184. Meunier F., Aoun M., and Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: A randomized double-blind study of fluconazole vs. ketoconazole. Rev. Infect. Dis. 12 Suppl. 3 (1990) S364-S368
185. Michaelis G., Zeiler D., Biscoping J., Fussle R., and Hempelmann G. Function of the adrenal cortex during therapy with fluconazole in intensive care patients. Mycoses 36 (1993) 117-123
186. Milatovi C.D., and Voss A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 11 (1992) 395-402
187. Milliken S., Powles R., Jones A., and Helenglass G. Pharmacokinetics of oral fluconazole in autologous bone marrow transplantation recipients given TBI and high-dose melphalan. Transplant. Proc. 21 (1989) 3067
188. Mitra A.K., Thummel K.E., Kalhorn T.F., Kharasch E.D., Unadkat J.D., and Slattery J.T. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin. Pharmacol. Ther. 59 (1996) 332-340
189. Monahan B.P., Ferguson C.L., Killeavy E.S., Lloyd B.K., Troy J., and Cantilena Jr. J.R. Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 264 (1990) 2788-2790
190. Morns A.B., Sands M.L., Shiraki M., Brown R.B., and Ryczak M. Gallbladder and biliary tract candidiasis: Nine cases and review. Rev. Infect. Dis. 12 (1990) 483-489
191. P.K. Narang J. Schoenfelder J. Lavelle C.B. Trapnell B.A. Wynne J.R. Bianchine (1993). Lower incidence of MAC in AIDS patients on rifabutin prophylaxis with concomitant fluconazole. Natl. Conf. Hum. Retroviruses Relat. Infect., 1st, p. 106
192. Narang P.K., Trapnell C.B., Schoenfelder J.R., Lavelle J.P., and Bianchine J.R. Fluconazole and enhanced effect of rifabutin prophylaxis. N. Engl. J. Med. 330 (1994) 1316-1317
193. Negroni R., Taborda A., Robies A.M., and Archevala A. Itraconazole in the treatment of histoplasmosis associated with AIDS. Mycoses 35 (1992) 281-287
194. Neuvonen P.J., and Jalava K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60 (1996) 54-61
195. Nguyen M.H., Peacock J.E., Tanner D.C., Morris A.J., Nguyen Snydman M.L.D.R., Wagener M.M., and Yu V.L. Therapeutic approaches in patients with candidemia. Arch. Intern. Med. 155 (1995) 2429-2435
196. Nicolau D.P., Crowe H., Nightingale C.H., and Quintiliani R. Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients. J. Antimicrob. Chemother. 36 (1995) 395-401
197. Nomura J., and Ruskin J. Failure of therapy with fluconazole for candidal endophthal-mitis. Clin. Infect. Dis. 17 (1993) 888-889
198. Odds F.C. Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31 (1993) 463-471
199. Odds F.C., Webster C.E., and Abbott A.B. Antifungal relative inhibition factors: BAY1-9139, bifonazole, butoconazole, isoconazole, itraconazole (R51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J. Antimicrob. Chemother. 14 (1984) 105-114
200. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55 (1994) 481-485
201. Olkkola K.T., Ahonen J., and Neuvonen P.J. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. 82 (1996) 511-516
202. O'Reilly R.A., Goulart D.A., Kunze K.L., Neal J., Gibaldi M., Eddy A.C., and Trager W.F. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. 51 (1992) 656-667
203. Pappas P.G., Bradsher R.W., Chapman S.W., Kauffman C.A., Dine A., Cloud G.A., and Dismukes W.E. Treatment of blastomyco-sis with fluconazole. A pilot study. Clin. Infect. Dis. 20 (1995) 267-271 the NIAID Mycoses Study Group
204. Pappas P.G., Kauffman C.A., Perfect J., Johnson P.C., McKinsey D.S., Bamberger D.M., Hamill R., Sharkey P.K., Chapman W.S., and Sobel J.D. Alopecia associated with fluconazole therapy. Ann. Intern. Med. 123 (1995) 354-357
205. Patterson T.F., Andriole V.T., Zervos M.J., and Kauffman C.A. The epidemiology of pseudallescheriasis complicating transplantation: Nosocomial and community-acquired infection. Mycoses 33 (1990) 297-302
206. Patton P.R., Brunson M.E., Pfaff W.W., Howard R.J., Peterson J.C., Ramos E.L., and Karlix J.L. A preliminary report of diltiazem and ketoconazole. Their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 57 (1994) 889-892
207. Perez J.A., Johnson R.H., Caldwell J.W., Arsura E.L., and Nemecheck P. Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch. Intern. Med. 155 (1995) 1665-1668
208. Perfect J., and Durack D.T. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. J. Antimicrob. Chemother. 16 (1985) 81-86
209. Petersen E.A., Ailing D.W., and Kirkpatrick C.H. Treatment of chronic mucocutane-ous candidiasis with ketoconazole. A controlled clinical trial. Ann. Intern. Med. 93 (1980) 791-795
210. P. Phillips S. Shafran G. Garber C. Rotstein F. Smaill K. Williams J. Singer S. Ioannou and the Canadian Candidemia Study Group (1995). Fluconazole versus amphotericin B for candidemia in non-neutropenic patients: A multicenter randomized trial. Intersci. Conf. Antimicrob. Agents Chemother., 35th. San Francisco, Abstr. No. LM20
211. Piepponen T., Blomqvist K., Brandt H., Havu V., Hollmen A., Kohtamäki K., Lehtonen L., and Turjanmaa K. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J. Antimicrob. Chemother. 29 (1992) 195-205
212. Piper J.P., Golden J., Brown D., and Broestler J. Successful treatment of Scedosporium apiospermum suppurative arthritis with itraconazole. Pediatr. Infect. Dis. J. 9 (1990) 674-675
213. Piscitelli S.C., Goss T.F., Wilton J.H., D'Andrea D.T., Goldstein H., and Schentag J.J. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob. Agents Chemother. 35 (1991) 1765-1771
214. Pluss J.L., and Opal S.M. Pulmonary sporotrichosis: Review of treatment and outcome. Medicine (Baltimore) 65 (1986) 143-153
215. Pohjola-Sintonen S., Viitasalo M., Toivonen L., and Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur. J. Clin. Pharmacol. 45 (1993) 191-193
216. Pont A., Williams P.L., Loose D.S., Feldman D., Reitz R.E., Bochra C., and Stevens D.A. Ketoconazole inhibits adrenal steroid synthesis. Ann. Intern. Med. 97 (1982) 370-372
217. Pont A., Williams P.L., Azhar S., Reitz R.E., Bochra C., Smith E.R., and Stevens D.A. Ketoconazole blocks testosterone synthesis. Arch. Intern. Med. 142 (1982) 2137-2140
218. Pont A., Graybill J.R., Craven P.C., Galgiani J.N., Dismukes W.E., Reitz R.E., and Stevens D.A. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch. Intern. Med. 144 (1984) 2150-2153
219. Powderly W.G., Saag M.S., Cloud G.A., Robinson P., Meyer R.D., Jacobson J.M., Graybill J.R., Sugar A.M., McAuliffe V.J., Follansbee S.E., Tuazon C.U., Stern J.J., Feinberg J., Hafner R., and Dismukes W.E. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326 (1992) 793-798 the NIAIDS AIDS Clinical Trials Group and the NIAID Mycoses Study Group
220. Powderly W.G., Finkelstein D.M., Feinberg J., Frame P., He W., van der Horst C., Koletar S.L., Eyster M.E., Carey J., Waskin H., Hooton T.M., Hyslop N., Spector S.A., and Bozzette S.A. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332 (1995) 700-705 the NIAIDS AIDS Clinical Trials Group
221. Prentice A.G., Warnock D.W., Johnson S.A., Phillips M.J., and Oliver D.A. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J. Antimicrob. Chemother. 34 (1994) 247-252
222. Price M.F., LaRocco M.T., and Gentry L.O. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemother. 38 (1994) 1422-1424
223. Pursley T.J., Blomquist I.K., Abraham J., Andersen H.F., and Bartley J.A. Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. 22 (1996) 336-340
224. Reents S., Goodwin S.D., and Singh V. Antifungal prophylaxis in immunocompro-mised patients. Ann. Pharmacother. 27 (1993) 53-60
225. Restrepo A., Robledo J., Gomez I., Tabares A.M., and Gutierrez R. Itraconazole therapy in lymphagitic and cutaneous sporotrichosis. Arch. Dermatol. 122 (1986) 413-417
226. Rex J. Itraconazole-digoxin interaction. Ann. Intern. Med. 116 (1992) 525
227. Rex J., Rinaldi M.G., and Pfaller M.A. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39 (1995) 1-8
228. Rex J.H., Bennett J.E., Sugar A.M., Pappas P.G., van der Horst C.M., Edwards J.E., Washburn R.G., Scheld W.M., Karchmer A.W., Dine A.P., Levenstein M.J., and Webb C.D. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl.J. Med. 331 (1994) 1325-1330
229. Rezabek G.H., and Friedman A.D. Superficial fungal infections of the skin. Diagnosis and current treatment recommendations. Drugs 43 (1992) 674-682
230. Rogers T.E., and Galgiani J.N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 30 (1986) 418-422
231. Rose H.D., and Varkey B. Miconazole treatment of relapsed pulmonary blastomycosis. Am. Rev. Respir. Dis. 118 (1978) 403-408
232. Ross J.B., Levine B., Catanzaro A., Einstein H., Schillaci R., and Friedman P.J. Ketoconazole for treatment of chronic pulmonary coccidioidomycosis. Ann. Intern. Med. 96 (1982) 440-443
233. Saag M.S., and Dismukes W.E. Azole antifungal agents; Emphasis on new triazoles. Antimicrob. Agents Chemother. 32 (1988) 1-8
234. Saag M.S., Powderly W.G., Cloud G.A., Robinson P., Grieco M.H., Sharkey P.K., Thompson S.E., Sugar A.M., TuazonU C., Fisher J.F., Hyslop N., Jacobson J.M., Hafner R., and Dismukes W.E. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl.J. Med. 326 (1992) 83-89 the NIAID Mycoses Study Group and the AIDS Clinical Trials Group
235. M. Saag, van der C. Horst G. Cloud R. Hamill R. Graybill J. Sobel P. Johnson C. Tuazon T. Kerkering J. Fisher H. Henderson J. Stansell D. Mildvan L. Riser D. Schneider R. Hafner C. Thomas B. Weisinger B. Moskovitz, the NIAID AIDS Clinical Trials Group and the Mycoses Study Group (1995a). (Part 2) Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) followed by a comparison of fluconazole to itraconazole (Step 2) in the treatment of cryptococcal meningitis in patients with AIDS. Intersci. Conf. Antimicrob. Agents Chemother. 35th, San Francisco, Abstr. No.1217
236. M. Saag G.C. Cloud R. Graybill J. Sobel C. Tuazon B. Wiesinger L. Riser, Moskovitz, B. L, W.E. Dismukes and the NIAID Mycoses Study Group (1995b). Camparison of fluconazole vs. itraconazole as maintenance therapy of AIDS-associated cryptococal meningitis. Intersci. Conf. Antimicrob. Agents Chemother. 35th, San Francisco, Abstr. No.1218
237. Sachs M.K., Blanchard L.M., and Green P.J. Interaction of itraconazole and digoxin. Clin. Infect. Dis. 16 (1993) 400-403
238. Sangeorzan J.A., Bradley S.F., He X., Zarins L.T., Ridenour G.L., Tiballi R.N., and Kauffman C.A. Epidemiology of oral candidiasis in HIV infected patients: Colonization, infection, treatment and emergence of fluconazole resistance. Am. J. Med. 97 (1994) 339-347
239. Sanglard D., Kuchler K., Ischer F., Pagani J.L., Monod M., and Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39 (1995) 2378-2386
240. Schaffner A., and Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis. 172 (1995) 1035-1041
241. Schenkman J.B., Remmer H., and Estabrook R.W. Spectral studies of drug interaction with hepatic microsomal cytochrome. Mol. Pharmacol. 3 (1967) 113-123
242. Seaton T.L., Celum C.L., and Black D.L. Possible potentiation of warfarin by fluconazole. DICP 24 (1990) 1777-1778
243. Shadomy S., Paxton L., Espinel-Ingroff A., and Shadomy J. In vitro studies with miconazole and miconazole nitrate. J. Antimicrob. Chemother. 3 (1977) 147-152
244. Shadomy S., White S.C., Yu H.P., and Dismukes W.E. Treatment of systemic mycoses with ketoconazole: In vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J. Infect. Dis. 152 (1985) 1249-1256
245. Sharkey P.K., Graybill J.R., Rinaldi M.G., Stevens D.A., Tucker R.M., Peterie J.D., Hoeprich P.D., Greer D.L., Frenkel L., Counts G.W., Goodrich J., Zellner S., Bradsher R.W., van der Horst C.M., Israel K., Pankey G.W., and Barranco C.P. Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. 23 (1990) 577-586
246. Sharkey P.K., Rinaldi M.G., Dunn J.F., Hardin T.C., Fetchick R.J., and Graybill J.R. High-dose itraconazole in the treatment of the severe mycoses. Antimicrob. Agents Chemother. 35 (1991) 707-713
247. Sharkey-Mathis P.K., Kauffman C.A., Graybill J.R., Stevens D.A., Hostetler J.S., Cloud G., and Dismukes W.E. Treatment of sporotrichosis with itraconazole. Am. J. Med. 95 (1993) 279-285 the NIAID Mycoses Study Group
248. Slavin M.A., Osborne B., Adams R., Levenstein M.J., Schoch H.G., Feldman A.R., Meyers J.D., and Bowden R.A. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. Clin. Infect. Dis. 171 (1995) 1545-1552
249. Smith A.G. Potentiation of oral anticoagulants by ketoconazole. Br. Med. J. 288 (1984) 188-189
250. Smith D.E., Midgley J., Allan M., Connolly G.M., and Gazzard B.G. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 5 (1991) 1367-1371
251. Smith D.E., Van de Velde V., Woestenborghs R., and Gazzard B.G. The pharmacoki-netics of oral itraconazole in AIDS patients. J. Pharm. Pharmacol. 44 (1992) 618-619
252. Sobel J.D. Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N. Engl. J. Med. 315 (1986) 1455-1458
253. Sobel J.D. Candidal vulvovaginitis. Clin. Obstet. Gynecol. 36 (1993) 153-165
254. Stein G.E., and Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob. Agents Chemother. 36 (1993) 89-92
255. Stevens D.A. Miconazole in the treatment of systemic fungal infections. Am. Rev. Respir. Dis. 116 (1977) 801-806
256. Stevens D.A. Coccidioidomycosis. N. Engl. J. Med. 332 (1995) 1077-1092
257. Stevens D.A., Levine H.B., and Deresinski S.C. Miconazole in coccididioidomycosis. II. Therapeutic and pharmacologic studies in man. Am. J. Med. 60 (1976) 191-202
258. Sugar A.M., Saunders C., Idelson B.A., and Bernard D.B. Interaction of fluconazole and cyclosporine. Ann. Intern. Med. 110 (1989) 844
259. Symoens J., Moens M., Dom J., Scheijgrond H., Dony J., Schuermans V., Legendre R., and Finestine N. An evaluation of two years of clinical experience with ketoconazole. Rev. Infect. Dis. 2 (1980) 674-687
260. Tarbit M.H., Robertson W.R., and Lambert A. Hepatic and endocrine effects of azole antifungal agents. In: Ryley J.F. (Ed). "Chemotherapy of Fungal Diseases" (1990), Springer-Verlag, New York 205-229
261. Tett S., Moore S., and Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob. Agents Chemother. 39 (1995) 1835-1841
262. Thaler F., Bernard B., Tod M., Jedynak C.P., Petitjean D., Derome P., and Loirat P. Fluconazole penetration in cerebral parenchyma in humans at steady state. Antimicrob. Agents Chemother. 39 (1995) 1154-1156
263. Thorpe J.E., Baker N., and Bromet-Petit M. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob, Agents Chemother. 34 (1990) 2032-2033
264. Tiballi R.N., Zanns L.T., He X., and Kauffman C.A. Torulopsis glabrata: Azole susceptibilities by microdilution colorimetric and macrodilution broth assays. J. Clin. Microbiol. 33 (1995) 2612-2615
265. Tobin J.M., Loo P., and Granger S.E. Treatment of vaginal candidosis: A comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin. Med. 68 (1992) 36-38
266. Toon S., Ross C.E., Gokal R., and Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br. J. Clin. Pharmacol. 29 (1990) 221-226
267. Touchette M.A., Chandrasekar P.H., Milad M.A., and Edwards D.J. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br. J. Clin. Pharmacol. 34 (1992) 75-78
268. Trapnell C.B., Narang P.K., Li R., Lewis R., Colborn D., and Lavelle J. Fluconazole increases rifabutin absorption in HIV (+) patients on stable zidovudine therapy. Int. Conf. AIDS 9 (1993) 504 (Abstr. No. PO-B31-2212)
269. Tucker R.M., Williams P.L., Arathoon E.G., Levine B.E., Hartstein A.I., Hanson L.H., and Stevens D.A. Pharmacokinetics of fluconazole incerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 32 (1988) 369-373
270. Tucker R.M., Denning D.W., Arathoon E.G., Rinaldi M.G., and Stevens D.A. Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations. J. Am. Acad. Dermatol. 23 (1990) 593-601
271. Tucker R.M., Denning D.W., Dupont B., and Stevens D.A. Itraconazole therapy for chronic coccidioidal meningitis. Ann. Intern. Med. 112 (1990) 108-112
272. Tucker R.M., Haq Y., Denning D.W., and Stevens D.A. Adverse events associated with itraconazole in 189 patients on chronic therapy. J. Antimicrob. Chemother. 26 (1990) 561-566
273. Tucker R.M., Denning D.W., Hanson L.H., Rinaldi M.G., Graybill J.R., Sharkey P.K., Pappagianis D., and Stevens D.A. Interaction of azoles with rifampin, phenytoin and carbamazepine: In vitro and clinical observations. Clin. Infect. Dis. 14 (1992) 165-174
274. Tucker W.S., Snell B.B., Island D.P., and Gregg C.R. Reversible adrenal insufficiency induced by ketoconazole. J. Am. Med. Assoc. 253 (1985) 2413-2414
275. Tunkel A.R., Thomas C.Y., and Wispelway B. Candida prosthetic arthritis: Report of a case treated with fluconazole and review of the literature. Am. J. Med. 94 (1993) 100-103
276. Uno J., Shigematsu M.L., and Arai T. Primary site of action of ketoconazole on Candida albicans. Antimicrob. Agents Chemother. 21 (1982) 912-918
277. Vanden H. Bossche 1987 Itraconazole: A selective inhibitor of the cytochrome P-450 dependent ergosterol biosynthesis "Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents" R. A. Fromtling), pp. 207-221
278. Prous J.R., Barcelona Vanden Bossche H., Marichal P., Odds F., Lejeune L., and Coene M.C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents. Chemother. 36 (1992) 2602-2610
279. Vanden Bossche H., Warnock D.W., Dupont B., Kerridge D., Gupta S.S., Improvisi L., Marichal P., Odds F.C., Provost F., and Ronin O. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32 (1994) 189-202
280. van der C. Horst M. Saag G. Cloud R. Hamill R. Graybill J. Sobel P. Johnson C. Tuazon T. Kerkering J. Fisher H. Henderson J. Stansell D. Mildvan L. Riser D. Schneider R. Hafner C. Thomas B. Weisinger B. Moskovitz, The MAID AIDS Clinical Trials Group and the Mycoses Study Group (1995). (Part 1) Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (Step 1) followed by a comparison of fluconazole to itraconazole (Step 2) in the treatment of cryptococcal meningitis in patients with AIDS. Intersc. Conf. Antimicrob. Agents Chemother., 35th, San Francisco, Abstr. No. 1216
281. Varhe A., Olkkola K.T., and Neuvonen P.J. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 56 (1994) 601-607
282. Varhe A., Olkkola K.T., and Neuvonen P.J. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. 41 (1996) 319-323
283. I. Vincent V. Furlan D. Debray E. Jacquemin A.M. Taburet (1995). Effects of antifungal agents on the pharmacokinetics and nephrotoxicity of FK506 in paediatric liver transplant recipients. Intersc. Conf. Antimicrob. Agents Chemother., 35th, San Francisco, Abstr. No. A24
284. Viscoli C., Castagnola E., Fioredda F., Ciravegna B., Barigione G., and Terragna A. Fluconazole in the treatment of candidiasis in immunocompromised children. Antimicrob. Agents Chemother. 35 (1991) 365-367
285. Viviani M.A., Tortorano A.M., Pagano A., Vigevani G.M., Gubertini G., Cristina S., Assaisso M.L., Suter F., Farina C., Minetti R., Faggian G., Caretta M., Di Fabrizio N., and Vaglia A. European experience with itraconazole in systemic mycoses. J. Am. Acad. Dermatol. 23 (1991) 587-593
286. Voice R.A., Bradley S.F., Sangeorzan J.A., and Kauffman C.A. Chronic candidal meningitis: An uncommon manifestation of candidiasis. Clin. Infect. Dis. 19 (1994) 60-66
287. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Harmatz J.S., and Shader R.I. Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 38 (1994) 23-31
288. von Moltke L.L., Greenblatt D.J., Duan S.X., Harmatz J.S., and Shader R.I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 34 (1994) 1222-1227
289. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., and Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 268 (1994) 1278-1283
290. Voss A., Meis J.F., and Hoogkamp-Korstanje G.M.J.A.A. Fluconazole in the management of fungal urinary tract infection. Infection 22 (1994) 247-251
291. Vu Van H., Piens M.A., Archimbaud E., Monier M.F., Guyotat D., Mojon M., and Fiere D. Serum levels of ketoconazole in bone marrow transplanted patients. Nouv. Rev. Fr. Hematol. 25 (1983) 241-244
292. Wahllander A., and Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur. J. Clin. Pharmacol. 37 (1989) 79-83
293. Wallbridge D.R., McCartney A.C., and Richardson M.D. Fluconazole in the treatment of Candida prosthetic valve endocarditis. Mycoses 36 (1993) 259-261
294. Walsh T.J., Foulds G., and Pizzo P.A. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob. Agents Chemother. 33 (1989) 467-469
295. Walsh T.J., Peter J., McGough D.A., Fothergill A.W., Rinaldi M.G., and Pizzo P.A. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39 (1995) 1361-1364
296. Weinstein L., and Jacoby I. Successful treatment of cerebral cryptococcoma and meningitis with miconazole. Ann. Intern. Med. 93 (1980) 569-571
297. Wheat L.J., Connolly-Stringfield P.A., Baker R.L., Curfman M.F., Eads M.E., Israel K.S., Norris S.A., Webb D.H., and Zeckel M.L. Disseminated histoplasmosis in the acquired immune deficiency syndrome: Clinical findings, diagnosis and treatment and review of the literature. Medicine (Baltimore) 69 (1990) 361-374
298. Wheat L.J., Hafner R., Wulfsohn M., Spencer P., Squires K., Powderly W., Wong B., Rinaldi M., Saag M., Hamill R., Murphy R., Connolly-Stringfield P., Briggs N., and Owens S. Prevention of relapse of histoplasmosis with itraconazole in patients with acquired immunodeficiency syndrome. Ann. Intern. Med. 118 (1993) 610-616 the NIAID Mycoses Study Group
299. Wheat J., Hafner R., Korzun A.H., Limjoco M.T., Spencer P., Larsen R.A., Hecht F.M., and Powderly W. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98 (1995) 336-342 the AIDS Clinical Trials Group
300. White A., and Goetz M.B. Azole-resistant Candida albicans: Report of two cases of resistance to fluconazole and review. Clin. Infect. Dis. 19 (1994) 687-692
301. White A., and Goetz M.B. Candida parapsilosis prosthetic joint infection unresponsive to treatment with fluconazole. Clin. Infect. Dis. 20 (1995) 1068-1069
302. White D.J., Blatchford N.R., and Cauwenbergh G. Cyclosporine and ketoconazole. Transplantation 37 (1984) 214-215
303. Whittle D.I., and Kominos S. Use of itraconazole for treating subcutaneous phaeohy-phomycosis caused by Exophiala jeanselmei. Clin. Infect. Dis. 21 (1995) 1068
304. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., and Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325 (1991) 1274-1277
305. Wingard J.R., Merz W.G., Rinaldi M.G., Miller C.B., Karp J.E., and Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemotber. 37 (1993) 1847-1849
306. Winn R.E., Anderson J., Piper J., Aronson N.E., and Pluss J. Systemic sporotrichosis treated with itraconazole. Clin. Infect. Dis. 17 (1993) 210-217
307. Chandrasekar D.J.P.H.W., Lazarus H.M., Goodman J.L., Silber J.L., Horowitz H., Shadduck R.K., Rosenfeld C.S., Ho W.G., Islam M.Z., and Buell D.N. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann. Intern. Med. 118 (1993) 495-503
308. Wise G.J., Goldman W.M., Goldberg P.E., and Rothenberg R.G. Miconazole: A cost-effective antifungal genitourinary irrigant. J. Urol. 138 (1987) 1413-1415
309. Yeh J., Soo S.C., Summerton C., and Richardson C. Potentiation of action of warfarin by itraconazole. Br. Med. J. 301 (1990) 669
310. Yu R. Successful treatment of chromoblastomycosis with itraconazole. Mycoses 38 (1995) 79-83
311. Zervos M., Silverman J., and Meunier F. Fluconazole in fungal infection: A review. Infect. Dis. Clin. Pract. 3 (1994) 94-101
312. Zimmermann M., Duruz H., Guinand O., Broccard O., Levy P., Lacatis D., and Bloch A. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur. Heart J. 13 (1992) 1002-1003
313. Zimmermann T., Yeates R.A., Riedel K.D., Lach P., and Laufen H. The influence of gastric pH on the pharmacokinetics of fluconazole: The effect of omeprazole. Int. J. Clin. Pharmacol. Ther. 32 (1994) 491-496
314. Zuckerman J.M., and Tunkel A.R. Itraconazole: A new triazole antifungal agent. Infect. Control Hosp. Epidemiol. 15 (1994) 397-410